FDA Approval For RET Cancer Drug Gavreto
Recently FDA Okayed Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer. Gavreto approved under the FDA’s accelerated approval…
Recently FDA Okayed Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer. Gavreto approved under the FDA’s accelerated approval…